Salivary Gland Cancer Treatment in India
Expert salivary gland cancer treatment in India — parotidectomy with facial nerve preservation, radiation therapy, and systemic treatment. Top head and neck oncologists.
Estimated cost: $4,000 – $8,000 · Average stay: 5–8 days
Salivary gland cancers — malignant tumors arising from the major salivary glands (parotid, submandibular, sublingual) or minor salivary glands scattered throughout the oral cavity and pharynx — are uncommon malignancies, representing approximately 6 cases per 100,000 people annually. They encompass a diverse array of histological subtypes with widely varying behaviors — from the indolent to the highly aggressive.
The parotid gland is the most common site (70–80% of all salivary gland tumors), though benign pleomorphic adenoma greatly outnumbers malignant parotid tumors. Mucoepidermoid carcinoma is the most common salivary gland malignancy overall; adenoid cystic carcinoma (ACC), salivary duct carcinoma, acinic cell carcinoma, and polymorphous adenocarcinoma are other important subtypes.
The most critical surgical consideration in parotid cancer is the facial nerve — the nerve controlling all facial expression muscles — which runs through the parotid gland. Expert head and neck oncological surgeons perform parotidectomy with meticulous facial nerve identification, stimulation, and preservation in every case where the nerve is not directly invaded by tumor. Sacrifice of the facial nerve — causing permanent facial paralysis — is reserved for cases of definitive nerve invasion.
India's head and neck oncology centers, driven by high volumes of head and neck cancer cases, have developed deep surgical expertise in parotidectomy and all forms of major salivary gland surgery, including complex reconstructive procedures for advanced disease.
Types of Salivary Gland Cancer
Salivary gland cancers are histologically diverse:
Mucoepidermoid carcinoma (MEC): the most common salivary malignancy. Low-grade tumors behave indolently and are cured by surgery. High-grade tumors are aggressive and require adjuvant radiation ± chemotherapy.
Adenoid cystic carcinoma (ACC): the most common malignant tumor of the submandibular and minor salivary glands. Characterized by perineural invasion (spread along nerve pathways) and a propensity for late distant metastasis to the lungs. Slow growing but rarely cured in advanced disease.
Salivary duct carcinoma: aggressive, high-grade malignancy resembling breast ductal carcinoma histologically. Frequently HER2-positive, which has treatment implications. Poor prognosis.
Acinic cell carcinoma: low-grade; cured by surgery in most cases. Rare late recurrences.
Ex-pleomorphic adenoma (carcinoma ex-PA): malignant transformation within a longstanding benign pleomorphic adenoma. Prognosis depends on extent of invasive component.
AJCC staging applies to parotid tumors; T1–T2 confined to gland, T3–T4 with extraparenchymal extension or bone involvement. Nodal and distant metastasis follow standard N and M criteria.
Who Is a Candidate for Salivary Gland Cancer Treatment?
All patients with confirmed malignant salivary gland tumors require surgical treatment as the primary modality.
Parotidectomy candidates: all parotid tumors — whether superficial lobe (lateral to facial nerve) or deep lobe — require parotidectomy. Superficial parotidectomy removes the lateral lobe. Total parotidectomy removes the entire parotid gland. Facial nerve identification and preservation are mandatory unless direct nerve invasion is confirmed.
Submandibular gland excision candidates: all submandibular malignancies require complete gland excision with adequate soft tissue margins and ipsilateral selective neck dissection.
Neck dissection candidates: selective neck dissection of levels II–IV is performed for all high-grade salivary malignancies, for T3–T4 tumors, or when clinical lymph node involvement is present.
Adjuvant radiation candidates: high-grade histology, T3–T4 stage, positive or close margins, lymph node involvement, or perineural invasion are all indications for adjuvant radiation. Neutron beam radiation — available at very few centers worldwide — may offer advantages for ACC.
HER2-positive salivary duct carcinoma: trastuzumab and pertuzumab (HER2-targeted therapy) show activity in advanced HER2-positive salivary duct carcinoma.
Parotidectomy and Salivary Gland Surgery
Parotidectomy is performed through a modified Blair incision along the posterior auricle and into the upper neck. The facial nerve is identified at its exit from the stylomastoid foramen at the base of the skull using anatomical landmarks and intraoperative nerve monitoring. All branches of the facial nerve are meticulously dissected to the periphery before any parotid tissue is removed.
For superficial parotid malignancies: lateral (superficial) parotidectomy removes all tissue lateral to the facial nerve with adequate deep margins. If the tumor extends beyond the superficial lobe, total parotidectomy is performed with preservation of the facial nerve if uninvaded.
Free flap reconstruction: when facial nerve sacrifice is required for extensive tumor invasion, facial nerve graft reconstruction (using the great auricular nerve or sural nerve graft) and facial reanimation procedures (temporalis muscle transposition, static facial reanimation) are offered.
Submandibular gland excision: removes the gland en-bloc through a small horizontal neck incision. The marginal mandibular branch of the facial nerve is meticulously protected. Wharton's duct is ligated and divided.
Procedure Steps
- Diagnostic ultrasound and fine-needle aspiration cytology (FNAC) for tissue diagnosis.
- MRI parotid/neck with gadolinium for T staging; CT for bone involvement or distant metastases.
- Multidisciplinary head and neck tumor board review.
- Total parotidectomy with intraoperative facial nerve monitoring; selective or modified radical neck dissection.
- Intraoperative frozen section of deep margins and facial nerve margin if nerve is preserved.
- If HER2 testing indicated (salivary duct carcinoma): IHC/FISH for HER2 status.
- Adjuvant IMRT radiation (60–66 Gy to tumor bed + regional nodes) for high-grade/advanced disease.
- For HER2-positive advanced disease: trastuzumab + pertuzumab ± docetaxel.
Salivary Gland Cancer Treatment Approaches
Total Parotidectomy with Facial Nerve Preservation
Complete removal of the parotid gland with meticulous facial nerve identification and preservation using intraoperative nerve monitoring. The fundamental principle of parotid oncologic surgery. Requires experienced head and neck surgeons who perform high volumes of parotidectomy.
Cost: $4,000 – $8,000
Adjuvant IMRT Radiation
Intensity-modulated radiation therapy (60–66 Gy) to the tumor bed and regional lymph nodes after salivary gland surgery for high-risk features. Significantly reduces local recurrence risk in high-grade histology, T3–T4 disease, and close or positive surgical margins.
Cost: $4,000 – $8,000 (full course)
Trastuzumab + Pertuzumab (HER2-Positive)
HER2-targeted therapy for HER2-overexpressing salivary duct carcinoma — analogous to breast cancer HER2-targeted treatment. Response rates of 40–60% in HER2-positive salivary duct carcinoma. Combined with docetaxel as first-line systemic treatment for advanced disease.
Cost: $1,500 – $3,500 per cycle
Platinum-Based Chemotherapy (Metastatic)
Cisplatin or carboplatin + paclitaxel for metastatic or inoperable salivary gland cancers without HER2 overexpression. Used as first-line palliative systemic therapy. Response rates of 20–35%. Clinical trials of androgen deprivation therapy for androgen receptor-positive tumors are ongoing.
Cost: $800 – $2,000 per cycle
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
India — $4,000 – $8,000 — Save 65–75%
UAE — $7,000 – $13,000 — Save 50–60%
USA / UK — $15,000 – $35,000+ — Baseline
Salivary gland cancer surgery in India is managed by experienced head and neck oncologists who perform high volumes of parotidectomies — with established facial nerve preservation expertise. Total parotidectomy plus adjuvant radiation in India costs $7,000–$14,000 total, compared to $40,000–$80,000 in the USA.
Recovery & Follow-up
Hospital stay after parotidectomy is 2–4 days. A surgical drain is removed after 1–2 days. Temporary facial weakness is expected from nerve retraction and typically improves over weeks to months. Frey's syndrome (sweating while eating) develops in some patients and is managed with topical antiperspirant. After submandibular gland excision, stay is 1–2 days. Adjuvant radiation starts 4–6 weeks after surgery and runs for 6–6.5 weeks.
Recovery Tips
- Facial weakness from nerve manipulation improves gradually — physical therapy and facial exercises speed recovery.
- If permanent facial nerve sacrifice was required, facial reanimation surgery can be planned 6–12 months later.
- Dry eye management (lubricating eye drops, eye taping at night) is critical if the upper facial nerve branches were involved.
- Attend all oncology follow-up appointments — adenoid cystic carcinoma in particular has a propensity for very late (10–20 year) distant recurrence.
- Report any new swelling around the parotid region or neck — local recurrence is the most common early failure pattern.
Risks & Complications
Parotidectomy risks include temporary facial weakness (from nerve retraction, 15–30% — usually recovers), permanent facial paralysis (if nerve sacrifice required — rare when nerve is not directly invaded), Frey's syndrome, wound hematoma, salivary fistula, and first bite syndrome. Radiation risks include xerostomia (dry mouth), trismus, and osteoradionecrosis. Neck dissection adds lymphedema and shoulder dysfunction risk.
Why GAF Healthcare
Gaf Healthcare connects salivary gland cancer patients with India's most experienced head and neck oncology teams — surgeons who perform high annual volumes of parotidectomy with nerve monitoring and have deep expertise in the complex histologic diversity of salivary gland malignancies. We coordinate HER2 testing and treatment planning for advanced disease.
Frequently Asked Questions
What is the survival rate for salivary gland cancer?
Prognosis varies significantly by histology and stage. Low-grade mucoepidermoid carcinoma: 5-year survival >90%. High-grade mucoepidermoid and salivary duct carcinoma: 5-year survival 40–60%. Adenoid cystic carcinoma: 5-year survival 75–80%, but 15-year survival only 30–35% due to late recurrences. Acinic cell carcinoma: 5-year survival >85%.
Will I have facial paralysis after parotid surgery?
Permanent facial paralysis is NOT a routine outcome of parotidectomy. The facial nerve is identified, monitored, and preserved in virtually all parotidectomies — even for malignant tumors — unless the nerve is directly invaded by cancer. Temporary weakness from nerve manipulation recovers in 80–90% of patients within weeks to months.
What is Frey's syndrome?
Frey's syndrome (auriculotemporal syndrome) occurs in 10–30% of patients after parotidectomy — the skin overlying the parotid area sweats during eating due to aberrant reinnervation of skin sweat glands by parasympathetic fibers. It is managed with topical botulinum toxin injections or antiperspirant cream applied to the affected skin.
Is adenoid cystic carcinoma curable?
ACC is often controlled for many years with surgery ± radiation, but true cure is uncommon in intermediate and high-grade cases due to perineural spread and propensity for late lung metastases — sometimes appearing 10–20 years after initial treatment. Regular surveillance is lifelong. Novel therapies targeting c-KIT mutations and other molecular drivers are in clinical trials.
Does salivary duct carcinoma respond to HER2 therapy?
Yes. Approximately 20–40% of salivary duct carcinomas overexpress HER2. These tumors, analogous to HER2-positive breast cancer, show meaningful responses to trastuzumab + pertuzumab ± docetaxel, with response rates of 40–60%. HER2 testing (immunohistochemistry followed by FISH for 2+ cases) should be performed on all salivary duct carcinomas.